We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Amphion Innovations Plc | LSE:AMP | London | Ordinary Share | GB00B0DJNP99 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.15 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMAMP
RNS Number : 3582Y
Amphion Innovations PLC
05 December 2017
AMPHION INNOVATIONS PLC
("Amphion" or "the Company")
Share Issuance
London and New York, Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, today announces that the Company has issued 1,664,659 ordinary shares, representing 0.80% of the enlarged issued share capital, to a holder ("Note Holder") of the Convertible Promissory Notes December 2008 - December 2017 (the "CPN"). The Note Holder is converting its CPN Holding of GBP133,172.76 into Amphion ordinary shares at 8 pence per share.
An application has been made for the new ordinary shares to be admitted to trading on AIM. Admission of the 1,664,659 new ordinary shares, ranking pari passu with the existing ordinary shares, is expected on 8 December 2017. Following this allotment, the total issued share capital of the Company will be 209,175,888 ordinary shares with each ordinary share holding one voting right. This figure may be used by shareholders in the Company as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").
For further information please contact:
Hot Features
Premium
Amphion Innovations Tel: +1 (212) 210 6224
Charlie Morgan
Panmure Gordon Limited (Nominated Tel: +44 (0)20
Adviser and Corporate Broker) 7886 2500
Freddy Crossley / Ryan McCarthy
(Corporate Finance)
Charlie Leigh-Pemberton
(Corporate Broking)
Northland Capital Partners Tel: +44 (0)20 3861
Limited (Joint Corporate Broker) 6625
Patrick Claridge / David
Hignell (Corporate Finance)
John Howes (Corporate
Broking)
Walbrook PR Tel: +44 (0)20 7933 8780
or
Mike Wort/ Paul McManus amphion@walbrookpr.com
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.
On the web: www.amphionplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOELFFFIFDLSIID
(END) Dow Jones Newswires
December 05, 2017 02:00 ET (07:00 GMT)
1 Year Amphion Innovations Chart |
1 Month Amphion Innovations Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
